Novonesis (NSIS) EGM 2024 summary
Event summary combining transcript, slides, and related documents.
EGM 2024 summary
26 Oct, 2026Specific resolutions to be voted on
Adopted a secondary name and amended the Articles of Association accordingly.
Elected Jesper Brandgaard as Vice Chair of the Board of Directors.
Elected Lise Kaae, Kevin Lane and Kim Stratton as Board members.
Board and executive committee updates
Following the meeting, Jesper Brandgaard became Vice Chair; Lise Kaae, Kevin Lane and Kim Stratton joined the Board.
The Board also includes Chair Cornelis (Cees) de Jong, Heine Dalsgaard, Sharon James, Kasim Kutay and Morten Otto Alexander Sommer.
Employee representatives are Anne Breum, Anders Hentze Knudsen, Preben Nielsen and Jens Øbro; Karen Louise Lauesen and Kim Ib Sørensen serve as observers.
Corporate governance
The Articles of Association were amended to reflect adoption of a secondary name.
Latest events from Novonesis
- 9M organic growth reached 7% and margin 37.9%; Human Health weakness and investment weighed.NSIS
Q3 2026 - FY2020 report approved; DKK 5.25 dividend retained and Board leadership re-elected.NSIS
AGM 2021 - 2021 report approved; dividend rose 5%, and Morten Sommer joined the Board.NSIS
AGM 2022 - A DKK 6.00 dividend and key Board and governance resolutions were approved.NSIS
AGM 2023 - Raised full-year sales growth outlook to 7-8% after 8% organic growth and EUR 1bn buyback.NSIS
Q2 2026 - Strong 2024 results; shareholders approved the dividend, elections, and key authorizations.NSIS
AGM 2025 - Diversification and innovation support biofuel growth and emerging SAF opportunities.NSIS
Status Update - 2024 outlook upgraded with higher growth and margins, driven by innovation and synergies.NSIS
CMD 2024 - 11% organic sales growth, margin expansion, and a major acquisition highlight Q1 2025.NSIS
Q1 2025